Top Midday Gainers

MT Newswires Live2025-02-07

Lipella Pharmaceuticals (LIPO) shares soared 79% after the company said Thursday it received a US Food and Drug Administration approval for an expanded access program for LP-310, an oral rinse formulation designed to treat oral lichen planus.

Over 82.1 million shares traded intraday versus a daily average of roughly 127,000.

TransCode Therapeutics (RNAZ) said Thursday that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The dose administered to patients in the cohort was about double that of Cohort 2.

Shares jumped nearly 33% as intraday trading volume climbed to more than 11.7 million from a daily average of over 1.44 million.

Tapestry (TPR) reported Thursday higher fiscal Q2 non-GAAP earnings and net sales while raising its outlook for fiscal 2025.

Shares rose roughly 13%, with intraday trading volume rising to nearly 10.6 million, compared with a daily average of more than 4.87 million.

Price: 4.69, Change: +2.07, Percent Change: +79.05

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2509005322?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-07 02:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509005322","market":"sh","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> Lipella Pharmaceuticals (LIPO) shares soared 79% after the company said Thursday it received a US Food and Drug Administration approval for an expanded access program for LP-310, an oral rinse formulation designed to treat oral lichen planus.</p><p>Over 82.1 million shares traded intraday versus a daily average of roughly 127,000.</p><p>TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RNAZ) said Thursday that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The dose administered to patients in the cohort was about double that of Cohort 2.</p><p>Shares jumped nearly 33% as intraday trading volume climbed to more than 11.7 million from a daily average of over 1.44 million.</p><p>Tapestry (TPR) reported Thursday higher fiscal Q2 non-GAAP earnings and net sales while raising its outlook for fiscal 2025.</p><p>Shares rose roughly 13%, with intraday trading volume rising to nearly 10.6 million, compared with a daily average of more than 4.87 million.</p><p>Price: 4.69, Change: +2.07, Percent Change: +79.05</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-07 02:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Lipella Pharmaceuticals (LIPO) shares soared 79% after the company said Thursday it received a US Food and Drug Administration approval for an expanded access program for LP-310, an oral rinse formulation designed to treat oral lichen planus.</p><p>Over 82.1 million shares traded intraday versus a daily average of roughly 127,000.</p><p>TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RNAZ) said Thursday that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The dose administered to patients in the cohort was about double that of Cohort 2.</p><p>Shares jumped nearly 33% as intraday trading volume climbed to more than 11.7 million from a daily average of over 1.44 million.</p><p>Tapestry (TPR) reported Thursday higher fiscal Q2 non-GAAP earnings and net sales while raising its outlook for fiscal 2025.</p><p>Shares rose roughly 13%, with intraday trading volume rising to nearly 10.6 million, compared with a daily average of more than 4.87 million.</p><p>Price: 4.69, Change: +2.07, Percent Change: +79.05</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0310800965.SGD","symbol_name":"FTIF - Templeton Global Balanced A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2509005322","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509005322","pubTimestamp":1738867391,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lipella Pharmaceuticals  shares soared 79% after the company said Thursday it received a US Food and Drug Administration approval for an expanded access program for LP-310, an oral rinse formulation designed to treat oral lichen planus.Over 82.1 million shares traded intraday versus a daily average of roughly 127,000.TransCode Therapeutics  said Thursday that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The dose administered to patients in the cohort was about double that of Cohort 2.Shares jumped nearly 33% as intraday trading volume climbed to more than 11.7 million from a daily average of over 1.44 million.Tapestry  reported Thursday higher fiscal Q2 non-GAAP earnings and net sales while raising its outlook for fiscal 2025.Shares rose roughly 13%, with intraday trading volume rising to nearly 10.6 million, compared with a daily average of more than 4.87 million.Price: 4.69, Change: +2.07, Percent Change: +","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","RNAZ":"TransCode Therapeutics  Inc.","BK4588":"碎股","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LIPO":"Lipella Pharmaceuticals Inc","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4585":"ETF&股票定投概念","BK4202":"服装、服饰与奢侈品","TPR":"Tapestry Inc.","BK4539":"次新股","BK4516":"特朗普概念","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4139":"生物科技"},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIPO":0.9,"TPR":0.9,"RNAZ":0.9},"content_text":"Lipella Pharmaceuticals (LIPO) shares soared 79% after the company said Thursday it received a US Food and Drug Administration approval for an expanded access program for LP-310, an oral rinse formulation designed to treat oral lichen planus.Over 82.1 million shares traded intraday versus a daily average of roughly 127,000.TransCode Therapeutics (RNAZ) said Thursday that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The dose administered to patients in the cohort was about double that of Cohort 2.Shares jumped nearly 33% as intraday trading volume climbed to more than 11.7 million from a daily average of over 1.44 million.Tapestry (TPR) reported Thursday higher fiscal Q2 non-GAAP earnings and net sales while raising its outlook for fiscal 2025.Shares rose roughly 13%, with intraday trading volume rising to nearly 10.6 million, compared with a daily average of more than 4.87 million.Price: 4.69, Change: +2.07, Percent Change: +79.05","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2509005322","isCrawlerRequest":true}